// App-Quantinova.ai

: Safety of Guselkumab in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Clinical Studies

Researchers

Presenter

  • Mark Lebwohl

Principal Investigators

  • Katelyn Rowl

  • Megan Miller

  • Ya-Wen Yang

  • Jenny Yu

  • Yin You

  • Daphne Chan

  • Richard G. Langley

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Research & Development, LLC, Spring House/Horsham, PA, USA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Dalhousie University, Halifax, Nova Scotia, Canada.

Locations

  • United States

  • Philippines

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved